An association study of a polymorphism in the heparan sulfate proteoglycan gene (perlecan, HSPG2) and Alzheimer's disease

Am J Med Genet B Neuropsychiatr Genet. 2004 Jul 1;128B(1):123-5. doi: 10.1002/ajmg.b.30015.

Abstract

Accumulating evidence indicates that the heparan-sulfate-proteoglycan (perlecan, HSPG2), as well as other specific proteoglycans, are involved in amyloidogenesis and tau aggregation in Alzheimer's disease (AD). Moreover, the HSPG2 is located on chromosome 1p36, a region of linkage to late-onset AD (LOAD). These two criteria, pathological and positional, make the HSPG2 an interesting candidate for an association with AD. We performed a case-control association study between the common intron 6 BamHI polymorphism at a region of putative heparan-sulfate (HS) attachment sites in the HSPG2 gene and sporadic AD in Jews. No association was detected with AD, neither as a risk factor nor as a modifier gene affecting the age at disease onset and disease progression. In addition, no interactive effect was found with the known risk factor for AD, the apolipoprotein E (APOE) epsilon4. These findings show no evidence for association between HSPG2 intron 6 BamHI polymorphism and AD in our population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age of Onset
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / epidemiology
  • Alzheimer Disease / genetics*
  • Apolipoprotein E4
  • Apolipoproteins E / genetics
  • Case-Control Studies
  • Deoxyribonuclease BamHI
  • Disease Progression
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Genotype
  • Heparan Sulfate Proteoglycans / genetics*
  • Humans
  • Introns
  • Jews / genetics
  • Middle Aged
  • Polymorphism, Genetic*

Substances

  • Apolipoprotein E4
  • Apolipoproteins E
  • Heparan Sulfate Proteoglycans
  • Deoxyribonuclease BamHI